Newsletter - May 11, 2017
Clinical Trials Cannot Catch All Side Effects of Drugs; Should We Worry?
This week an article in JAMA reported that about a third of all new drugs approved by FDA in the 10 year period from 2001-2010 had “safety events” after approval which led to about 1% of the drugs being withdrawn from market. This number may be concerning to some, but a careful review of the context shows that this information is clinically less significant that it seems to appear. Read More
Privacy Concerns Limit Use of Genetic Data from DTC Tests
Of the 48 major categories of direct-to-consumer (DTC) genetic and genomic tests available to consumers, the tests for ancestry dominate the number of people and tests being done, followed far behind by those for health-related general information. By some estimates in the US alone more than 5 million individuals have had their genomes sequenced for determining ancestry. Read More
Clinical Trials Cannot Catch All Side Effects of Drugs; Should We Worry?
This week an article in JAMA reported that about a third of all new drugs approved by FDA in the 10 year period from 2001-2010 had “safety events” after approval which led to about 1% of the drugs being withdrawn from market. This number may be concerning to some, but a careful review of the context shows that this information is clinically less significant that it seems to appear. Read More
Privacy Concerns Limit Use of Genetic Data from DTC Tests
Of the 48 major categories of direct-to-consumer (DTC) genetic and genomic tests available to consumers, the tests for ancestry dominate the number of people and tests being done, followed far behind by those for health-related general information. By some estimates in the US alone more than 5 million individuals have had their genomes sequenced for determining ancestry. Read More
